MyFinsight
Home
Blog
About
Receivables-Nonrelated Party
$1,020,360K
(26.34%↑ Y/Y)
Inventories
$677,954K
(11.33%↑ Y/Y)
Cash and cash
equivalents
$127,637K
(78.40%↑ Y/Y)
Prepaid expenses and
other current assets
$112,011K
(31.31%↑ Y/Y)
Restricted cash
$8,643K
(-10.36%↓ Y/Y)
Receivables-Related Party
$424K
(-73.37%↓ Y/Y)
Total current assets
$1,947,029K
(22.86%↑ Y/Y)
Goodwill
$593,499K
(-0.65%↓ Y/Y)
Intangible assets, net
$587,830K
(-9.50%↓ Y/Y)
Property, plant and
equipment, net
$456,877K
(3.76%↑ Y/Y)
Other assets
$80,669K
(79.87%↑ Y/Y)
Financing lease
right-of-use...
$52,360K
(-4.92%↓ Y/Y)
Operating lease
right-of-use...
$44,361K
(33.45%↑ Y/Y)
Operating lease
right-of-use assets-Related...
$13,723K
(-22.28%↓ Y/Y)
Total assets
$3,776,348K
(10.33%↑ Y/Y)
Total liabilities and
stockholders equity...
$3,776,348K
(10.33%↑ Y/Y)
Total long-term
liabilities
$2,776,181K
(17.52%↑ Y/Y)
Total current
liabilities
$883,187K
(-20.23%↓ Y/Y)
Redeemable
non-controlling interests
$83,956K
(27.59%↑ Y/Y)
Total stockholders
equity (deficiency)
$33,024K
(129.35%↑ Y/Y)
Long-term debt, net
$2,564,335K
(19.47%↑ Y/Y)
Liabilities for legal
matters - long term
$70,830K
(-4.90%↓ Y/Y)
Financing lease
liabilities-Nonrelated Party
$54,602K
(-2.53%↓ Y/Y)
Operating lease
liabilities-Nonrelated Party
$38,691K
(40.07%↑ Y/Y)
Related party payables -
long...
$32,119K
(24.42%↑ Y/Y)
Operating lease
liabilities-Related Party
$12,712K
(-22.68%↓ Y/Y)
Related party payables -
long term-Related...
$2,892K
(-81.47%↓ Y/Y)
Accounts payable and
accrued...
$721,208K
(8.16%↑ Y/Y)
Revolving credit facility
$100,000K
(-65.52%↓ Y/Y)
Accounts payable and
accrued...
$22,070K
(-65.19%↓ Y/Y)
Current portion of
liabilities for legal...
$18,488K
(-55.47%↓ Y/Y)
Current portion of
operating lease...
$9,040K
(9.94%↑ Y/Y)
Current portion of
long-term debt, net
$5,961K
(-80.88%↓ Y/Y)
Current portion of
financing lease...
$3,521K
(6.47%↑ Y/Y)
Current portion of
operating lease...
$2,899K
(7.33%↑ Y/Y)
Total amneal
pharmaceuticals, inc....
$33,024K
(129.45%↑ Y/Y)
Stockholders accumulated
deficit
-$415,087K
(27.49%↑ Y/Y)
Accumulated other
comprehensive loss
-$100,666K
(-3.32%↓ Y/Y)
Additional paid-in capital
$545,584K
(-1.63%↓ Y/Y)
Common stock-Common
Class A
$3,193K
(1.69%↑ Y/Y)
Back
Back
Balance Sheet
Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX)
source: myfinsight.com